Conatus Pharmaceuticals Inc. (CNAT) Hit 12-Month Low on Apr, 16 at $3.63

April 16, 2018 - By Ashley Edward

Big Money Sentiment decreased to 1.1 in 2017 Q4. It has change of 0.73, from 2017Q3’s 1.83. The ratio turned negative due to Conatus Pharmaceuticals Inc. positioning: 14 sold and 17 reduced. 11 funds acquired stakes and 23 increased stakes. Investors holded 10.89 million in 2017Q3 but now own 11.71 million shares or 7.58% more.
Citadel Advsr Limited Co accumulated 0% or 13,425 shs. Arrowstreet Cap Lp reported 0% stake. D E Shaw & owns 45,382 shs. Royal Bankshares Of Canada holds 1,143 shs or 0% of its capital. 24,100 are held by State Common Retirement Fund. The New York-based Tower Cap Lc (Trc) has invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). California State Teachers Retirement Systems invested in 0% or 41,439 shs. Legal & General Gru Pcl, United Kingdom-based fund reported 3,776 shs. Wells Fargo & Mn holds 0% or 34,036 shs in its capital. Barclays Public Ltd Com owns 4,170 shs. California Public Employees Retirement Systems has invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Parallax Volatility Advisers L P stated it has 3,906 shs or 0% of all its holdings. Strs Ohio reported 26,700 shs. Alliancebernstein L P owns 10,800 shs. Mpm Asset Mgmt holds 3.89% or 2.10 million shs in its capital.

The company Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) broke into 1-year low with $3.41 price target or 6.00 % below today’s $3.63 stock price. Barchart.com reported the 1-year low on Apr, 16. It has $109.12 million market cap. At $3.41 stock price target, the company valuation changes by $6.55 million less.

The stock decreased 5.71% or $0.22 during the last trading session, reaching $3.63.Conatus Pharmaceuticals Inc. has volume of 360,692 shares. Since April 16, 2017 CNAT has risen 12.92% and is uptrending. CNAT outperformed by 1.37% the S&P 500.

Analysts await Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report earnings on May, 3. They expect $-0.17 earnings per share, down 21.43 % or $0.03 from last year’s $-0.14 per share. After $-0.15 actual earnings per share reported by Conatus Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 13.33 % negative EPS growth.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Ratings Coverage

Total analysts of 4 have positions in Conatus Pharmaceuticals (NASDAQ:CNAT) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since February 8, 2018 according to StockzIntelligence Inc Conatus Pharmaceuticals has 6 analyst reports. On Thursday, April 5 the stock has “Buy” rating by H.C. Wainwright. The stock rating was initiated by Oppenheimer with “Buy” on Thursday, March 1. On Wednesday, March 7 the firm has “Buy” rating by Oppenheimer given. On Thursday, March 22 the stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) earned “Buy” rating by Oppenheimer.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States.The company has $109.12 million market cap. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response.Last it reported negative earnings.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.